Factors Correlated to the Renoprotective Effect of Sitagliptin in Patients with Type 2 Diabetes Mellitus: Retrospective Observational Study.
與 Sitagliptin 在 2 型糖尿病患者中腎保護效果相關的因素:回顧性觀察研究。
Adv Pharmacol Pharm Sci 2024-09-09
Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes.
第二線抗高血糖藥物對慢性腎臟疾病風險的影響:將目標試驗方法應用於泰國第二型糖尿病患者的醫院基礎群。
Cardiovasc Diabetol 2024-03-20
Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: A propensity-matched cohort study.
在較低的HbA1c閾值下開始使用鈉葡萄糖共轉運蛋白2抑製劑可減緩2型糖尿病患者腎臟過濾率下降,無論是否合併心腎疾病:一項傾向匹配的同期研究。
Diabetes Res Clin Pract 2023-02-10
Sitagliptin Mitigates Diabetic Nephropathy in a Rat Model of Streptozotocin-Induced Type 2 Diabetes: Possible Role of PTP1B/JAK-STAT Pathway.
Sitagliptin 在一個 Streptozotocin-誘導的第2型糖尿病大鼠模型中緩解糖尿病腎病變:PTP1B/JAK-STAT 途徑的可能作用。
Int J Mol Sci 2023-04-15
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study.
與2型糖尿病患者對鈉葡萄糖共轉運輸蛋白2抑制劑反應之臨床和實驗室因素的關聯:一項回顧性觀察性研究。
Expert Opin Pharmacother 2024-06-01
Liraglutide combined with routine therapy improves renal function, renal fibrosis, immune status, and prognosis of type 2 diabetes patients.
Liraglutide 與常規療法聯合使用改善 2 型糖尿病患者的腎功能、腎纖維化、免疫狀態及預後。
Am J Transl Res 2024-08-08
Effects on calcium phosphate homeostasis after sodium-glucose cotransporter 2 inhibitor in patients with advanced chronic kidney disease and type 2 diabetes mellitus.
在晚期慢性腎病和第二型糖尿病患者中,鈉-葡萄糖共轉運蛋白 2 抑制劑對鈣磷穩態的影響。
Diabetes Res Clin Pract 2024-08-11
Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world.
SGLT-2 抑制劑對於真實世界中 2 型糖尿病患者腎功能影響的回顧性分析。
Front Pharmacol 2024-08-20
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
接受常規護理的2型糖尿病患者中,使用SGLT2抑制劑或GLP-1受體激動劑的匹配隊列比較腎臟結果。
Diabetologia 2024-08-23